Howard G. Smith MD, AM on Instagram: "New Relief For Women In Menopause The hot flashes and night sweats of menopause create a miserable midlife for so many women. Hormones do offer relief, but many women cannot take them. Enter a new non-hormonal drug just approved by the FDA. This medication, elinzanetant to be marketed as Lynkuet by Bayer, GlaxoSmithKline, and Nerre Therapeutics, is an oral neurokinin/tachykinin antagonist that normalizes thermal and sleep regulation. A phase 3 multi-national study headed by researchers at the University of Virginia School of Medicine shows that 120 mg elinzanetant taken daily relieves both the frequency and intensity of hot flashes, improves sleep quality, and elevates moods. Improvement occurred for some study participants within the first week of therapy. Last year, the FDA approved another Bayer oral menopause drug fezolinetant, branded as Veozah. With one neurokinin receptor blocker, it reduces hot flashes only. This year’s new entry is more powerful as it blocks two neurokinin receptors and affects not only thermoregulation, the hot flashes, but also sleep and mood. Since these drugs contain no estrogen, they lack the risks of blood clots, possible strokes, or exacerbation of certain hormone-dependent cancers including breast, uterine, and ovarian. Once readily available at your pharmacy, they provide safe, effective, and non-hormonal options for controlling bothersome menopausal symptoms. Currently not approved for women with pre- or peri-menopausal symptoms, that approval should come soon, https://medicalxpress.com/news/2025-10-fda-nonhormonal-drug-ease-menopause.html https://newsroom.uvahealth.com/2025/09/16/drug-reduces-hot-flashes-by-73-trial-finds/ #women #elinzanetant #Lynkuet #menopaue #hotflashes #nightsweats"

Get the facts on the new non-hormonal menopause treatment, Lynkuet, and how it can alleviate hot flashes, improve sleep, and elevate moods, without the risks associated with estrogen-based treatments.